Skip to main content

#Coronavirus Disease Research #References (by AMEDEO, May 10 '25)

Image
By G.M.

 


    Antiviral Res

  1. MARTIN HJ, Hossain MA, Wellnitz J, Kelestemur E, et al
    Chemical arsenal for helicase Hunters: Striking the toughest targets in antiviral research.
    Antiviral Res. 2025;239:106184.
    PubMed         Abstract available


    Int J Infect Dis

  2. BANHOLZER N, Middelkoop K, Schmutz R, Leukes J, et al
    Infection prevention and control measures during the COVID-19 pandemic and airborne tuberculosis transmission during primary care visits in South Africa.
    Int J Infect Dis. 2025 May 6:107921. doi: 10.1016/j.ijid.2025.107921.
    PubMed         Abstract available


    J Infect

  3. RIEDMANN U, Chalupka A, Richter L, Werber D, et al
    Underlying health biases in previously-infected SARS-CoV-2 vaccination recipients: a cohort study.
    J Infect. 2025 Apr 30:106497. doi: 10.1016/j.jinf.2025.106497.
    PubMed         Abstract available


    J Med Virol

  4. MAZZOTTA V, Lepri AC, Del Borgo C, Lanini S, et al
    Comparative Analysis of Early COVID-19 Treatment Efficacy in a Multicentric Regional Cohort in Italy: Emulation of a Series of Target Trials.
    J Med Virol. 2025;97:e70379.
    PubMed         Abstract available

  5. CENAT JM, Moshirian Farahi SMM, Dalexis RD, Muray M, et al
    COVID-19 Vaccine Uptake Rates and Associated Factors in Racially Diverse Parents in Canada: The Threat From Conspiracy Beliefs and Racial Discrimination.
    J Med Virol. 2025;97:e70376.
    PubMed         Abstract available

  6. SANCHEZ-SIMARRO A, Panizo N, Gimenez E, Albert E, et al
    Dynamics of SARS-CoV-2 Spike Receptor-Binding Domain-Targeted Specific Peripheral Memory B Cells in Patients With End-Stage Chronic Kidney Disease Undergoing Replacement Therapy Following COVID-19 Vaccination.
    J Med Virol. 2025;97:e70382.
    PubMed         Abstract available

  7. YANG H, Gao L, Xue Y, Zhang Z, et al
    Clinical Characteristics and Treatment Efficacy in Patients With SARS-CoV-2 Positivity After Nirmatrelvir-Ritonavir Therapy.
    J Med Virol. 2025;97:e70377.
    PubMed         Abstract available

  8. ZHANG R, Li D, Gao P, Ruan W, et al
    A SARS-CoV and SARS-CoV-2 RBD Heterodimer Vaccine Candidate.
    J Med Virol. 2025;97:e70367.
    PubMed         Abstract available


    J Virol

  9. DAI J, Feng Y, Long H, Liao Y, et al
    Dexamethasone disrupts intracellular pH homeostasis to delay coronavirus infectious bronchitis virus cell entry via sodium hydrogen exchanger 3 activation.
    J Virol. 2025 May 9:e0189424. doi: 10.1128/jvi.01894.
    PubMed         Abstract available

  10. LUGANO D, Mwangi K, Mware B, Kibet G, et al
    Characterization of SARS-CoV-2 intrahost genetic evolution in vaccinated and non-vaccinated patients from the Kenyan population.
    J Virol. 2025 May 6:e0048225. doi: 10.1128/jvi.00482.
    PubMed         Abstract available


    JAMA

  11. RUDMAN SPERGEL AK, Wu I, Deng W, Cardona J, et al
    Immunogenicity and Safety of Influenza and COVID-19 Multicomponent Vaccine in Adults >/=50 Years: A Randomized Clinical Trial.
    JAMA. 2025 May 7:e255646. doi: 10.1001/jama.2025.5646.
    PubMed         Abstract available


    Nature

  12. MALLAPATY S
    Trump freezes 'gain of function' pathogen research - threatening all US virology, critics say.
    Nature. 2025 May 7. doi: 10.1038/d41586-025-01411.
    PubMed        

  13. KIYONO H, Ernst PB
    Nasal vaccines for respiratory infections.
    Nature. 2025;641:321-330.
    PubMed         Abstract available
Labels:

Comments

Post a Comment

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

By G.M.
{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...
Post a Comment
Read more »

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

By G.M.
Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...
Post a Comment
Read more »

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

By G.M.
Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...
Post a Comment
Read more »